Although our study is unique in examining these biomarkers in mildly symptomatic SARS-CoV-2-positive young adults, our results agree with three other studies which found that serum and plasma GFAP and NfL were not significantly different in healthy controls compared to COVID-19 patients with mild symptoms23,26,29 and also agrees with studies that have not found significant differences of plasma and serum tau31,32 in COVID-19 patients compared to healthy controls. This evidence concerns the gene GFAP and COVID-19.